IP Library Granted Patent US 7,112,609
Granted Patent B2
US 7,112,609 · App. 10/457,647 · Granted Sep 26, 2006

Nutritional supplements

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,112,609
App. No.
10/457,647
Granted
Sep 26, 2006
Kind
B2
Abstract

The present disclosure relates to novel nutritional methods and compositions containing essential fatty acids which optimize embryonic, fetal and child neurological development and provide improved nutritional support for women prior to and during lactation. Further the methods and compositions improve gestational length and birth weight. The nutritional methods and compositions are also intended for use by women to optimize infant neurological development and provide improved nutritional support for women prior to, during and after lactation.

Claims (15)

1. A method for providing nutritional supplements, the method comprising:

administering to a pregnant or lactating woman about 10 mg to 100 mg of a first fatty acid compound selected from the group consisting of a linoleic acid compound, a linolenic acid compound, linolenic acid salts, linoleic acid salts, linolenic acid esters, linoleic acid esters, linolenic acid glyceride esters, linoleic acid glyceride esters, gamma-linolenic acid, dihomo-gamma-linolenic acid, dihomo-gamma-linolenic acid esters, dihomo-gamma-linolenic acid endoperoxides, docosapentanoic acid, eicosapentaenoic acid, docosahexaenoic acid and a combination thereof;

about 10 mg to 1000 mg of a second fatty acid compound selected from the group consisting of a docosahexaenoic acid compound, an omega-3 fatty acid, an omega-2 fatty acid, eicosapentaenoic acid, docosapentanoic acid and a combination thereof;

about 10 mg to 125 mg of a vitamin B.sub.6 compound;

about 0.1 mg to 3 mg of a folic acid compound;

about 100 mg to 2,000 mg of a calcium compound;

about 25 mg to 500 mg of a vitamin C compound; and

about 10 mg to 400 mg of a vitamin E compound, wherein the weight ratio of said first fatty acid compound to said second fatty acid compound is about 1:0.1 to 10.

2. The method of claim 1 wherein the supplements are in an oral dosage form.

3. The method of claim 2 wherein the oral dosage form is selected from the group consisting of immediate release, extended release, pulsed release, delayed release, controlled release and combinations thereof.

4. The method of claim 2 , wherein said oral dosage form is selected from the group consisting of a chewable tablet, quick dissolve tablet, an effervescent tablet, a hard gelatin capsule, a soft gelatin capsule, reconstitutable particles, microparticles, a suspension, an elixir, a caplet and combinations thereof.

5. The method of claim 1 wherein the nutritional supplements further comprising administering a vitamin compound selected from the group consisting of a Vitamin A compound, a B complex vitamin compound, a Vitamin D compound and combinations thereof.

6. The method of 1 further comprising administering iron.

7. The method of claim 1 , wherein the administration occurs once during a twenty-four hour period.

8. The method of claim 1 , wherein the administration occurs at least twice during a twenty-four hour period.

Assignments (17)
MERGER AND CHANGE OF NAME Recorded Jan 3, 2018
From: AMAG PHARMACEUTICALS IP, LTD.; AMAG PHARMA USA, INC.
To: AMAG PHARMA USA, INC.
Reel/Frame 044523/0160 →
CHANGE OF NAME Recorded Dec 27, 2017
From: LUMARA HEALTH IP LTD.
To: AMAG PHARMACEUTICALS IP, LTD.
Reel/Frame 044961/0232 →
RELEASE OF SECURITY INTEREST Recorded May 15, 2017
From: JEFFERIES FINANCE LLC
To: LUMARA HEALTH IP LTD.
Reel/Frame 042461/0626 →
RELEASE OF SECURITY INTEREST Recorded Oct 9, 2015
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: LUMARA HEALTH IP LTD.
Reel/Frame 036763/0475 →
RELEASE OF SECURITY INTEREST Recorded Oct 1, 2015
From: WILLMINGTON TRUST, NATIONAL ASSOCIATION
To: LUMARA HEALTH IP LTD
Reel/Frame 036704/0822 →
SECURITY INTEREST Recorded Sep 25, 2015
From: LUMARA HEALTH IP LTD.
To: JEFFERIES FINANCE LLC
Reel/Frame 036653/0138 →
SECURITY INTEREST Recorded Nov 12, 2014
From: LUMARA HEALTH IP LTD
To: JEFFERIES FINANCE LLC
Reel/Frame 034156/0243 →
RELEASE OF SECURITY INTERESTS IN INTELLECTUAL PROPERTY Recorded Oct 20, 2014
From: LAW DEBENTURE TRUST COMPANY OF NEW YORK
To: K-V PHARMACEUTICAL COMPANY
Reel/Frame 034018/0040 →
CHANGE OF NAME Recorded Jul 9, 2014
From: DRUGTECH CORPORATION
To: LUMARA HEALTH IP LTD.
Reel/Frame 033282/0265 →
SECURITY AGREEMENT Recorded Sep 17, 2013
From: DRUGTECH CORPORATION
To: LAW DEBENTURE TRUST COMPANY OF NEW YORK, AS AGENT
Reel/Frame 031226/0883 →
SECURITY AGREEMENT Recorded Mar 18, 2011
From: DRUGTECH CORPORATION
To: WILMINGTON TRUST FSB (AS COLLATERAL AGENT)
Reel/Frame 025981/0068 →
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2011
From: U.S. HEALTHCARE I, LLC (AS ADMINISTRATIVE AND COLLATERAL AGENT)
To: DRUGTECH CORPORATION
Reel/Frame 025981/0934 →
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2011
From: U.S. HEALTHCARE, LLC (AS ADMINISTRATIVE AND COLLATERAL AGENT)
To: DRUGTECH CORPORATION
Reel/Frame 025980/0024 →
PATENT SECURITY AGREEMENT Recorded Nov 20, 2010
From: DRUGTECH CORPORATION
To: U.S. HEALTHCARE I, LLC
Reel/Frame 025385/0498 →
PATENT SECURITY AGREEMENT Recorded Sep 14, 2010
From: DRUGTECH CORPORATION
To: U.S. HEALTHCARE I, L.L.C.
Reel/Frame 024982/0344 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2006
From: KV PHARMACEUTICAL COMPANY
To: DRUGTECH CORPORATION
Reel/Frame 017366/0086 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2006
From: HERMELIN, MARC S.; LEVINSON, R. SAUL; PARADISSIS, GEORGE
To: KV PHARMACEUTICAL COMPANY
Reel/Frame 017353/0759 →